HUE050096T2 - Vegyület alkalmazásra neurodegeneratív betegségek megelõzésére és kezelésére - Google Patents
Vegyület alkalmazásra neurodegeneratív betegségek megelõzésére és kezeléséreInfo
- Publication number
- HUE050096T2 HUE050096T2 HUE16809318A HUE16809318A HUE050096T2 HU E050096 T2 HUE050096 T2 HU E050096T2 HU E16809318 A HUE16809318 A HU E16809318A HU E16809318 A HUE16809318 A HU E16809318A HU E050096 T2 HUE050096 T2 HU E050096T2
- Authority
- HU
- Hungary
- Prior art keywords
- prevention
- compound
- treatment
- neurodegenerative diseases
- neurodegenerative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15196984 | 2015-11-30 | ||
EP16156775.5A EP3207925A1 (en) | 2016-02-22 | 2016-02-22 | Compound for use in the prevention and treatment of neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE050096T2 true HUE050096T2 (hu) | 2020-11-30 |
Family
ID=57539219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE16809318A HUE050096T2 (hu) | 2015-11-30 | 2016-11-30 | Vegyület alkalmazásra neurodegeneratív betegségek megelõzésére és kezelésére |
Country Status (14)
Country | Link |
---|---|
US (1) | US11179358B2 (hu) |
EP (2) | EP3383381B1 (hu) |
JP (2) | JP7033073B2 (hu) |
CN (1) | CN108601758A (hu) |
AU (1) | AU2016364308B2 (hu) |
CA (1) | CA3003841A1 (hu) |
DK (1) | DK3383381T3 (hu) |
ES (1) | ES2804541T3 (hu) |
HU (1) | HUE050096T2 (hu) |
IL (1) | IL259383B (hu) |
MX (1) | MX2018006631A (hu) |
PT (1) | PT3383381T (hu) |
SG (2) | SG11201803422RA (hu) |
WO (1) | WO2017093363A1 (hu) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3986883A1 (en) * | 2019-06-18 | 2022-04-27 | Universität Wien | Calixarene compounds and uses thereof |
KR20240095008A (ko) * | 2022-11-22 | 2024-06-25 | 경북대학교 산학협력단 | 신경염증성 질환 치료효과를 나타내는 신규 펩타이드 및 이의 용도 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5489612A (en) * | 1991-08-23 | 1996-02-06 | The University Of Alabama At Birmingham Research Foundation | Calixarene chloride-channel blockers |
FR2782007B1 (fr) | 1998-08-05 | 2001-02-23 | Centre Nat Rech Scient | Utilisation des calix(n)arenes pour le traitement des maladies fibrotiques |
US8506959B2 (en) * | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
CN101052417A (zh) * | 2004-08-09 | 2007-10-10 | 艾兰制药公司 | 突触核蛋白病以及淀粉样变性病的预防和治疗 |
FR2888937B1 (fr) * | 2005-07-21 | 2012-10-26 | Biomerieux Sa | Procede de detection des fcpa utilisant un agent d'agregation des fcpa et un agent de capture des agregats formes |
CN101460157B (zh) | 2006-03-29 | 2015-09-02 | 维斯塔实验室有限公司 | 蛋白聚集抑制剂 |
WO2013134371A1 (en) | 2012-03-06 | 2013-09-12 | Neuropore Therapies, Inc. | Methods and compounds to be used in the treatment of neurodegenerative diseases |
-
2016
- 2016-11-30 PT PT168093185T patent/PT3383381T/pt unknown
- 2016-11-30 EP EP16809318.5A patent/EP3383381B1/en active Active
- 2016-11-30 MX MX2018006631A patent/MX2018006631A/es unknown
- 2016-11-30 SG SG11201803422RA patent/SG11201803422RA/en unknown
- 2016-11-30 US US15/779,559 patent/US11179358B2/en active Active
- 2016-11-30 IL IL259383A patent/IL259383B/en unknown
- 2016-11-30 EP EP20168424.8A patent/EP3735965A1/en not_active Withdrawn
- 2016-11-30 WO PCT/EP2016/079353 patent/WO2017093363A1/en active Application Filing
- 2016-11-30 CA CA3003841A patent/CA3003841A1/en not_active Abandoned
- 2016-11-30 AU AU2016364308A patent/AU2016364308B2/en active Active
- 2016-11-30 ES ES16809318T patent/ES2804541T3/es active Active
- 2016-11-30 CN CN201680069632.0A patent/CN108601758A/zh active Pending
- 2016-11-30 HU HUE16809318A patent/HUE050096T2/hu unknown
- 2016-11-30 JP JP2018546767A patent/JP7033073B2/ja active Active
- 2016-11-30 SG SG10202004908UA patent/SG10202004908UA/en unknown
- 2016-11-30 DK DK16809318.5T patent/DK3383381T3/da active
-
2021
- 2021-12-10 JP JP2021200877A patent/JP2022027864A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN108601758A (zh) | 2018-09-28 |
WO2017093363A1 (en) | 2017-06-08 |
EP3383381B1 (en) | 2020-04-08 |
PT3383381T (pt) | 2020-07-03 |
AU2016364308A1 (en) | 2018-05-17 |
SG11201803422RA (en) | 2018-06-28 |
US11179358B2 (en) | 2021-11-23 |
IL259383A (en) | 2018-07-31 |
EP3735965A1 (en) | 2020-11-11 |
AU2016364308B2 (en) | 2022-03-10 |
JP2022027864A (ja) | 2022-02-14 |
JP2018535272A (ja) | 2018-11-29 |
JP7033073B2 (ja) | 2022-03-09 |
EP3383381A1 (en) | 2018-10-10 |
ES2804541T3 (es) | 2021-02-08 |
MX2018006631A (es) | 2019-01-30 |
SG10202004908UA (en) | 2020-06-29 |
IL259383B (en) | 2022-07-01 |
DK3383381T3 (da) | 2020-07-13 |
CA3003841A1 (en) | 2017-06-08 |
US20200360315A1 (en) | 2020-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201607415B (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
ZA201908165B (en) | Compounds for the prevention and treatment of diseases and the use thereof | |
PL3277280T3 (pl) | Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych | |
IL281585B (en) | Selenogalactoside compounds for the prevention and treatment of galectin-related diseases and their use | |
GB201617064D0 (en) | Compounds and their therapeutic use | |
PL3197556T3 (pl) | KOMPOZYCJA DO ZAPOBIEGANIA l/LUB LECZENIA OBJAWÓW ALERGII | |
EP3107534A4 (en) | Compositions and methods for the treatment of neurodegenerative diseases | |
PT3413870T (pt) | Igmesina para utilização no tratamento de doença de alzheimer | |
EP3377062C0 (en) | AMINONAPHHOQUINONE COMPOUNDS FOR THE TREATMENT AND/OR PREVENTION OF FIBROSIS DISEASES | |
IL259383A (en) | A compound for use in the prevention and treatment of neurodegenerative diseases | |
EP3283457A4 (en) | Compounds and methods for the treatment of neurodegenerative diseases | |
PT3120852T (pt) | Agente preventivo e/ou terapêutico para doenças imunitárias | |
EP3208262A4 (en) | Compounds derived from 3-alkylamino-1h-indole acrylate, and the use thereof in the treatment of neurodegenerative diseases | |
HK1252359A1 (zh) | 用於治療疼痛的曲唑酮和加巴噴丁的組合 | |
HK1246271A1 (zh) | 用於合成羥基-三甘油酯的方法及其用於預防和治療疾病的用途 | |
IL252493A0 (en) | Compounds for use in the prevention or treatment of cancer | |
IL249440B (en) | Pharmaceutical compounds and preparations containing them for the treatment of neurodegenerative diseases | |
PT3191112T (pt) | Compostos de dipeptidilcetoamida e sua utilização para o tratamento e/ou prevenção da acumulação de gordura | |
IL257689B (en) | Pharmaceutical preparations and methods for treating diseases related to lack of oxygen | |
GB201518489D0 (en) | Methods for the treatment and prevention of ebola | |
AU2014904751A0 (en) | Methods for the treatment and prevention of asbestos-related diseases |